Call to Establish 'Centers of Excellence' for Pituitary Diseases
Article ID: 596346
Released: 20-Nov-2012 10:00 AM EST
Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins
Preliminary Proposal Suggests New Designation for Centers Offering Specialized Treatment, Training, and Research
Newswise — Philadelphia, Pa. (November 20, 2012) – The time has come to develop a pituitary "centers of excellence" (CoE) designation for hospitals with high-level surgical skills and other capabilities needed to provide state-of-the-art care for patients with pituitary tumors, according to an article in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Recent advances in surgical and medical management—along with the high prevalence and impact of pituitary tumors—warrant development of a voluntary system for designating pituitary centers of excellence, according to the special article by four leading U.S. neurosurgeons including Daniel Kelly and Nancy McLaughlin (John Wayne Cancer Institute & Saint John’s Health Center, Santa Monica, CA), Edward Laws, (Brigham & Women’s Hospital, Boston, MA) and Nelson Oyesiku (Emory University, Atlanta, GA), as well as a leading endocrinologist (Laurence Katznelson, Stanford University, Palo Alto, CA). Designation Recognizes Surgical Skills and Coordinated Care for Pituitary TumorsTumors of the pituitary gland, located directly under the brain in the skull base, pose difficult challenges in both diagnosis and treatment. Known as the body's "master gland," the pituitary produces hormones that control a wide range of bodily functions. In recent years, studies have shown that pituitary adenomas and other related tumors are more common than previously thought—affecting perhaps 1 out of 1,000 people. These tumors can lead to conditions of hormonal excess such as acromegaly, Cushing’s disease and prolactinoma, as well as hormonal loss, visual loss and headaches.
The idea of a CoE designation reflects specialized skills and expertise needed to provide top-level care for patients with particular types of problems. Perhaps the best-known example is the designation of level I to IV trauma centers, based on criteria such as the volume of severely injured patients treated, levels of specialist staffing, and the presence of educational and outreach programs.
The authors believe it's time for a similar approach to identifying hospitals and medical centers with the capacity to provide optimal clinical management for patients with pituitary tumors. Care is best provided in a "multidisciplinary collaborative environment," including neurosurgeons and endocrinologists with special experience in managing pituitary disorders. The treatment team should also include a wide range of other medical and surgical subspecialists who play important roles in managing these complex cases, such as neuro-ophthalmologists, radiation oncologists and otolaryngologists (ENT).
The call for a CoE designation reflects the rapid evolution of highly specialized surgical techniques for pituitary tumors, known as transsphenoidal surgery, increasingly performed with endoscopy, as well as new medical approaches to treating the hormonal abnormalities these tumors can produce. Advances in radiology and pathology have also raised the standard of skills needed for diagnosis and management.
As with other advanced surgical procedures, studies have shown that centers performing a larger volume of transsphenoidal surgeries achieve better outcomes with lower complication rates. Such high levels of volume and expertise are also essential for training the next generation of pituitary surgeons, who may not be getting the experience they need at some residency programs.
"[O]ptimal care for pituitary patients is best provided by experienced practitioners, working in a collaborative environment using state-of-the-art techniques and therapies," the authors write. They outline a "preliminary proposal" for a pituitary CoE designation, based on three key missions:• Providing comprehensive care and support to patients with pituitary disorders.• Providing residency training, fellowship training, and/or continuing medical education in the management of pituitary and neuroendocrine disease.• Contributing to research in pituitary disorders.
The authors acknowledge that many questions remain to be answered, such as what organization would oversee the effort and how to ensure that expertise is adequately distributed across regions. As time goes on, it will be important to show that pituitary centers of excellence are truly effective in improving patient outcomes and reducing health care costs. They conclude, "Such an effort would enhance patient care, increase public awareness, promote training and expertise, and advance research in the management of pituitary tumors and related hormonal disorders."###About NeurosurgeryNeurosurgery, the Official Journal of the Congress of Neurological Surgeons, is your most complete window to the contemporary field of neurosurgery. Members of the Congress and non-member subscribers receive 3,000 pages per year packed with the very latest science, technology, and medicine, not to mention full-text online access to the world's most complete, up-to-the-minute neurosurgery resource. For professionals aware of the rapid pace of developments in the field, Neurosurgery is nothing short of indispensable.
About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes. LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2011 annual revenues of €3.4 billion ($4.7 billion).